2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1010

IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Abstract Number: 95

IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Abstract Number: 2493

IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Abstract Number: 1707

IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Abstract Number: 1904

IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Abstract Number: 852

Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients
Abstract Number: 2922

Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis
Abstract Number: 286

Imaging Neoangiogenesis in Rheumatoid Arthritis (INIRA): Whole-Body Synovial Uptake of a 99mTc-Labelled RGD Peptide Is Highly Correlated with Power Doppler Ultrasound
Abstract Number: 715

Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review
Abstract Number: 1560

Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
Abstract Number: 1808

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
Abstract Number: 826

Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Abstract Number: 21

Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody
Abstract Number: 1376

Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Abstract Number: 479

Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].